September 2025 Novartis expanded its healthcare portfolio through continued investment in innovative anti-infective research and pharmaceutical development, supporting treatment solutions for bacterial and inflammatory conditions.
July 2025 Viatris expanded its global anti-infective pharmaceutical portfolio by strengthening availability of generic medicines used across infectious disease treatment areas, including therapies relevant to ENT infections.
June 2025 Pfizer expanded its anti-infective medicine portfolio by advancing development and commercialization initiatives for infection treatment therapies, supporting healthcare providers in managing bacterial infections.
May 2025 Cipla expanded its respiratory and ear, nose, and throat (ENT) healthcare portfolio by strengthening access to anti-infective and supportive treatment solutions used in managing ear-related infections.